To study the effects of high blood chloride levels on kidney related outcomes in patients who are severely ill because of infections.
Not Applicable
- Conditions
- Health Condition 1: N179- Acute kidney failure, unspecifiedHealth Condition 2: B95-B97- Bacterial and viral infectious agents
- Registration Number
- CTRI/2022/02/040519
- Lead Sponsor
- Dr Saurabh Maruti Thanekar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Admitted in medical ICUs during the study period
2. Diagnosis of sepsis (defined as suspected or documented infection and an acute increase of >=2 SOFA points) with or without septic shock (defined as sepsis AND vasopressor therapy needed to elevate MAP>=65mmHgandlactate >2mmol/L or >18 mg/dL despite adequate fluid resuscitation)
Exclusion Criteria
1. Baseline eGFR <15mL/min
2. Receiving dialysis at time of admission
3. ICU stay of less than 72 hours
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse kidney outcomes within 30 days (MAKE30)Timepoint: 30 days <br/ ><br>(Major adverse kidney outcomes within 30 days (MAKE30) <br/ ><br>MAKE30 is a composite of death, provision of dialysis, or sustained loss of kidney function (defined as a final inpatient creatinine value â?¥200% of the base line value)â??assessed at hospital discharge or 30 days after enrollment, whichever comes first)
- Secondary Outcome Measures
Name Time Method Individual components of the primary composite outcome <br/ ><br>Timepoint: o In-hospital mortality or mortality by day 30 <br/ ><br>o Requirement of dialysis by day 30 <br/ ><br>o Sustained loss of kidney function at day 30